PDGFRB and breast cancer: In breast cancer, while iCAFs (PDGFRB+, ACTA2-, CD34+, MCAM-) were implicated in cytotoxic T cell dysfunction of tripe-negative breast cancer (22), myCAFs (ecm) and myCAFs (TGFβ) were shown to be the primary resistance elements of immunotherapies (21).